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Introduction
The bacterial pathogen Helicobacter pylori infects the human stomach causing chronic inflammation of the gastric mucosa. Most infected individuals remain asymptomatic but a subset develop peptic ulcers, gastric adenocarcinomas, and mucosa-associated lymphoid tissue (MALT) lymphoma resulting from the infection. Disease risk depends on the severity and distribution of inflammation in the stomach. Those with inflammation that is predominantly in the antrum of the stomach are at higher risk for duodenal ulcer and those with inflammation that extends into the stomach corpus are at higher risk for gastric adenocarcinoma [1] . In those who eventually develop gastric adenocarcinoma, H. pylori-induced chronic inflammation initiates a pathological cascade that progresses from atrophy to intestinal metaplasia and dysplasia [2] . Density of H. pylori infection has been found to be correlated with level of inflammation [3, 4] but loss of H. pylori infection has been observed in atrophic gastric tissue [5] and increased pH in the stomach can promote growth of other bacteria [6] . Notably, H. pylori often cannot be detected within tumors and the association of H. pylori with cancer was strongest when H. pylori infection was assessed 10 years prior to cancer diagnosis [7] .
Bacterial genetic factors contribute in part to differences in bacterial density, inflammation, and disease development. The strain-variable cagA gene is associated with a higher risk of gastric adenocarcinoma development [8] . The cagA gene is located within the cag pathogenicity island that encodes a Type IV secretion system which delivers the CagA effector protein into host gastric epithelial cells [9] . Inside the host cell, the CagA protein is phosphorylated at EPIYA sites and the phosphorylated form is able to deregulate normal cellular signaling [10] [11] [12] [13] . The cagA gene is grouped into two different allele types, Western alleles that encode an EPIYA-C motif and East Asian alleles that encode an EPIYA-D motif. cagA alleles having an EPIYA-D motif are predominantly found in H. pylori strains circulating in East Asian countries and are associated with an increased risk of gastric cancer development compared to cagA alleles having an EPIYA-C motif [14] .
Studies investigating the role of the cagA gene in density of H. pylori infection in the stomach have produced conflicting results, with some studies reporting a significantly higher density of H. pylori infection in those with cagA-positive H. pylori [3, 15] and some finding no difference in bacterial density between cagA-positive and cagA-negative strains [4, 16, 17] . We recently reported development of a new, non-invasive method for detection, quantification, and cagA genotyping of H. pylori from stool samples that uses droplet digital PCR (ddPCR). We tested this method using a collection of matched serum and stool samples from volunteers in Costa Rica and observed a two log range of H. pylori loads in the stool. Furthermore, the H. pylori load in the stool was significantly higher in those with a cagA-positive strain [18] . However, the extent to which the H. pylori load in the stool reflects the load in the stomach is not clear.
To assess differences in H. pylori carriage and colonization density upon cancer development and to examine factors that contribute to the observed variability in H. pylori loads in stool, including H. pylori load in the stomach and cagA status, we applied the quantitative ddPCR assays to gastric mucosal brushing samples and stool samples collected from gastric cancer and non-cancer subjects from China.
Materials and methods

Study populations and specimen collection
To investigate possible differences in H. pylori carriage and load in the stomach as well as H. pylori shedding in stool, C14 urea breath test (UBT, Haidewei HUBT-01P) was used to screen individuals to be treated for gastric cancer or undergoing upper GI endoscopy for other indications at Henan Cancer Hospital between 2015.10.27-2016.03.15. Subjects who were H. pylori-positive by UBT were offered participation in this research study and all participants provided written informed consent prior to participation. Participating subjects had gastric mucosal brushings collected and were asked to fill out a questionnaire that covered demographic characteristics, medical conditions, and medications (S1 and S2 Questionnaires) and provide a stool sample. All procedures were approved by the Henan Cancer Hospital Medical Research Institution Review Board (doc # 2016oct005).
In total, samples were collected from 50 subjects including 25 gastric cancer subjects diagnosed by pathology who were undergoing gastric resection surgery and 25 non-cancer subjects with no history of gastric tumor or surgery who were undergoing upper GI endoscopy either as indicated because of symptoms (n = 8) or as asymptomatic volunteers (n = 16). All non-cancer cases that consented to collection of extra biopsies for histologic evaluation (n = 17) showed evidence of gastritis and no ulcers. All 50 subjects had not taken antibiotics for gastric disease in the past month.
Gastric mucosal brushing samples were collected from two different anatomical sites in the stomach, the antrum and the corpus, using cytology brushes (Puritan Medical Products Co LLC). Gastric mucosal brushings were collected and stored in a cryovial containing 1 ml flow media (minimal essential media plus 10% DMSO, 5% fetal calf serum, 5mM HEPES [19] . Cryovials containing the gastric mucosal brushing samples were immediately placed and kept at -80˚C. The gastric mucosal brushings were collected from the gastric cancer subjects during the gastric resection surgery and from non-cancer subjects during upper GI endoscopy. Stool samples were collected 1-2 days before either surgery or endoscopy. Participants undergoing surgery collected the stool sample at the hospital and participants undergoing endoscopy collected the stool sample at home and delivered it to the hospital on the same day. Stool samples were collected by the participants into a vial containing 5 ml RNAlater nucleic acid preservative (Ambion) and were frozen at -20˚C upon receipt. In addition to the gastric mucosal brushings and stool samples, gastric biopsies were collected for histological analysis. A gastric biopsy was collected from the antrum and the corpus from all gastric cancer cases and 17 noncancer cases. Gastric biopsies were formalin-fixed and paraffin-embedded prior to histological analysis.
DNA extraction
For the gastric mucosal brushings, sample media and brush were transferred from the cryovial to a microcentrifuge tube and centrifuged, followed by removal of the supernatant and brush. DNA was then extracted from the pellet using the UltraClean Tissue and Cells DNA Isolation Kit (MoBio) according to the manufacturer's instructions.
Stool samples were first transferred to a microcentrifuge tube and centrifuged to remove the RNAlater. DNA was then extracted using the QIAamp Stool DNA Mini Kit (Qiagen) according to the manufacturer's instructions, with the lysis step performed at 95˚C. Stool DNA concentration was measured using a NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Scientific), and the concentration was adjusted to 100 ng/μl.
Droplet digital PCR
H. pylori-specific droplet digital PCR (ddPCR) assays (H. pylori 16S assay, cagA detection assay, and cagA EPIYA typing assay) were performed using the QX200 ddPCR System (BioRad) as described previously [18] for stool DNA and gastric mucosal brushing DNA. Briefly, each 20 μl reaction contained 1x ddPCR Supermix for Probes (BioRad), 900 nM of each primer, 250 nM of probes, and 10 μl DNA. Reactions were subject to thermal cycling with the following conditions: 95˚C for 10 minutes, 45 cycles of 94˚C for 30 seconds and 55˚C for 1 minute, and a final incubation at 98˚C for 10 minutes. Data were analyzed using the QuantaSoft software version 1.6.6 (BioRad). The threshold was set to 4500 for the H. pylori 16S assay and 5500 for the cagA detection assay. For the cagA EPIYA assay, the thresholds were set to 4000 (both gastric and stool samples) for the FAM channel and 2500 (gastric samples) or 3000 (stool samples) for the HEX channel. A positive control (stool DNA from an H. pyloripositive volunteer) and negative control (molecular grade water) were included in each batch of samples analyzed.
For the gastric brushing samples, the copy number of H. pylori 16S was normalized to the copies of human DNA in the sample, as measured by a ddPCR assay for 18S. The following primers and probe were used in the 18S assay: 18SFor (5'-CGATGCTCTTAGCTGAGTG-3'), 18SRev (5'-CTTAATCATGGCCTCAGTTC-3'), and 18S_HEX (5' hexachloro-fluorescein-CCGCAGCTAGGAATAATGGAATAG-black hole quencher 3'). Reactions were subject to thermal cycling with the following conditions: 95˚C for 10 minutes, 45 cycles of 94˚C for 30 seconds and 59˚C for 1 minute, and a final incubation at 98˚C for 10 minutes. Data were analyzed using the QuantaSoft software version 1.6.6 (BioRad) and the threshold was set to 2000.
The concentration of the gastric mucosal brushing DNA sample was adjusted so that the copy number of the ddPCR assay target was within the dynamic range of the assay. DNA samples were run as either undiluted or diluted 1:10, 1:100, 1:1000, or 1:10,000. Stool DNA concentration was adjusted to 100 ng/μl as needed so that no more than 1 μg stool DNA was added to each ddPCR reaction.
Sanger sequencing of cagA EPIYA region
To investigate the presence and structure of cagA in samples negative for both EPIYA-C and EPIYA-D by ddPCR, we amplified gastric mucosa total DNA from the antrum sample with primers cag2 (5'-GGAACCCTAGTCGGTAATG-3')and cag4 (5'-ATCTTTGAGCTTGTC TATCG-3'). Reactions were subject to amplification with the following conditions: 98˚C for 10 seconds; 55 cycles of 98˚C for 10 seconds, 62˚C for 15 seconds and 72˚C for 45 seconds; final incubation at 72˚C for 5 minutes. The resulting PCR products were purified with QIAquick PCR Purification Kit (Qiagen) according to the manufacturer's instructions and submitted for Sanger sequencing to the FHCRC Genomics Shared Resource using primers cag2 and cag4. Sequences are available through GenBank accession numbers MH558342-8.
Histological analysis
For histological analysis of the gastric biopsies, slides were made from formalin-fixed paraffinembedded (FFPE) gastric tissue samples. Slides were stained with Wright-Giemsa stain (Baso Diagnostics, Inc. Zhuhai, China) according to the manufacturer's instructions. Stained slides were analyzed and scored as either normal (0), mild (1), moderate (2), or marked (3) according to the Sydney Classification System for H. pylori density, neutrophils, mononuclear cells, atrophy, and intestinal metaplasia [20] . For the non-cancer subjects, more than one anatomical site of the stomach was analyzed for a patient (i.e. antrum and corpus) and the H. pylori density, neutrophils, mononuclear cells, and intestinal metaplasia was scored as the average of the two sites. Atrophy was scored separately for the antrum and corpus. For the gastric cancer subjects, only gastric tissue from the carcinoma adjacent site was scored.
Statistical analysis
Correlation between gastric cancer and cagA allele was assessed using Fisher's Exact Test. The Wilcoxon Two-Sample Exact Test was used for comparisons of H. pylori loads between gastric cancer subjects and non-cancer subjects and between East Asian cagA allele and Western cagA allele groups. Correlation between H. pylori load in the gastric mucosal brushing samples from different anatomic sites and with H. pylori load in the stool was analyzed using Spearman Correlation Coefficients with Fisher's z-Transformation. All statistical analyses were performed in SAS version 9.4 (SAS Institute, Inc.).
Results
Gastric cancer cases show frequent evidence of active H. pylori infection
Of 58 gastric cancer subjects screened for H. pylori infection by UBT, 25 (43%) were H. pyloripositive. Of 108 non-cancer subjects screened, 25 (23%) were H. pylori-positive by UBT. One of the 25 participating non-cancer subjects did not provide an adequate stool sample and was excluded from the analysis. The remaining 49 subjects included in our study had a median age of 53 years (range 27 to 76 years) and included 15 (31%) females and 34 (69%) males. Of the 25 gastric cancer subjects, 22 (88%) were male compared to 12 (50%) of the 24 non-cancer cases. The gastric cancer cases had a median age of 59 years (range 46-76 years) and the non-cancer cases had a median age of 49 years (range 27-66 years).
Of the 49 subjects, histological slides of gastric biopsy were available for all 25 of the gastric cancer subjects and 17 of the non-cancer subjects consented to provide samples for histologic scoring of inflammation, pathological changes, and H. pylori density by the Sydney Classification System [20] . Level of neutrophil and mononuclear cell infiltration, indicating acute and chronic inflammation respectively, tended to be lower in the gastric cancer subjects, but distribution of scores for atrophy, intestinal metaplasia, and H. pylori density were similar between gastric cancer subjects and non-cancer subjects (Table 1) . Of the 42 subjects with histology slides analyzed, 13 (31%) had signs of atrophy and 18 (43%) had signs of intestinal metaplasia. Despite all subjects being positive for H. pylori infection by UBT, three subjects (two cancer cases and one non-cancer subject) did not have H. pylori detected by histology.
Cancer and non-cancer cases show similar loads of H. pylori in the stomach by ddPCR
To investigate the load of H. pylori in the stomach among subjects, we employed ddPCR to measure the copy number of the H. pylori 16S ribosomal RNA gene, a highly conserved gene present in all H. pylori strains, in total DNA extracted from mucosal brush samples from both the antrum and corpus for each subject. H. pylori load was normalized to the human 18S ribosomal RNA gene copy number present in each sample. The H. pylori 16S gene was detected in one or both gastric mucosal brushing samples of 22 (88%) of 25 gastric cancer subjects and all 24 (100%) non-cancer subjects. One non-cancer subject had H. pylori 16S detected in the sample from the corpus but not the antrum. Of the three subjects that did not have H. pylori detected by histology, one also did not have the H. pylori 16S gene detected by ddPCR in either gastric sample. The other two had low loads of H. pylori 16S detected by ddPCR (gastric H. pylori load of 10 and 0.4 16S copies per 1000 18S). As shown in Fig 1A, the load of H. pylori detected in gastric samples varied over several logs in both cancer and non-cancer subjects. For the gastric samples with detectable H. pylori 16S, the H. pylori 16S copy number per 1000 18S ranged from 0.003 to 1034 with a median of 144 for the antrum and ranged from 0.84 to 1967 with a median of 103 for the corpus. The H. pylori load in the antrum and corpus were significantly correlated (Spearman Correlation Estimate = 0.7, 95% CI: 0.5-0.8, Fig 1B) and for subsequent analysis we considered the gastric load to be the average of that measured for the antrum and corpus sample for each subject. The gastric H. pylori load between the gastric cancer cases (median = 139 H. pylori 16S copies per 1000 18S copies, range 0.9-386) and the noncancer subjects (median = 114 H. pylori 16S copies per 1000 18S copies, range 0.4-1150) was not significantly different (p = 0.4, Wilcoxon Exact Test).
Loss of acid secreting parietal cells and transformation of the gastric glands to an intestinal metaplasia phenotype as consequence of H. pylori induced inflammation has been suggested to favor outgrowth of other bacterial species over H. pylori. We saw similar proportions of intestinal metaplasia in cancer cases compared to non-cancer subjects (Table1). We thus checked whether gastric H. pylori load differed according to presence of intestinal metaplasia (Fig 1C) , but saw no significant difference (p = 0.3, Wilcoxon Exact Test). (18) a 0 = normal, 1 = mild, 2 = moderate, 3 = marked; score is for the carcinoma adjacent tissue of gastric cancer subjects and is the average of the antrum and corpus for non-cancer subjects.
https://doi.org/10.1371/journal.pone.0202925.t001 Gastric cancer cases and non-cancer subjects show similar variation in H. pylori load within the stomach and high concordance between antrum and corpus samples. A. Copy number of the H. pylori 16S ribosomal RNA genes was measured by ddPCR from gastric brushes collected from the stomach antrum or corpus and normalized to copy number of the human 18S ribosomal RNA gene. Cancer cases n = 25, non-cancer subjects n = 24. Box extends from 25 th to 75 th percentiles with a line at the median value. Whiskers show minimum and maximum values. In three cancer cases, no H. pylori DNA was detected and in one non-cancer subject, H. pylori was only detected in the corpus. These points are plotted on the X-axis. B. Correlation between corpus and antrum load (copy number of H. pylori 16S ribosomal gene) for subjects with H. pylori DNA detected in both samples. Cancer cases black, n = 22, non-cancer
Stool-based ddPCR detection of H. pylori 16S shows higher loads in gastric cancer cases and low correlation with gastric load
We next examined the relationship between detection and copy number of the H. pylori 16S ribosomal RNA gene by ddPCR in stool with detection and copy number in the stomach. Of the stool samples from gastric cancer cases, the H. pylori 16S gene was detected in 21 (84% of the 25 gastric cancer cases). Considering the 22 gastric cancer cases for which we detected the H. pylori 16S gene in the stomach, 21 (95%) also had detection in the stool. The H. pylori 16S gene was detected in 22 (92%) of the 24 stool samples from non-cancer subjects. For the stool samples with detectable H. pylori 16S, the H. pylori 16S copy number per μg stool DNA ranged from 2 to 1080 with a median of 26 (Fig 2A) . The H. pylori load in the stool was significantly higher (Wilcoxon Exact Test, p = 0.03) in the gastric cancer cases (median = 46 H.pylori 16S copies per μg stool DNA, range 0-560) compared to the non-cancer subjects (median = 7.5 H. pylori 16S copies per μg stool DNA, range 0-1080). The H. pylori load observed in the stool was weakly correlated with the H. pylori load in the gastric samples of the same subject (Spearman Correlation Estimate = 0.3, 95% CI:0.03-0.6, Fig 2B) .
ddPCR reveals variation in cagA alleles and association of East Asian cagA with gastric cancer
Previous studies suggest very high prevalence of cagA-positive strains and a predominance of East Asian EPIYA alleles in China [21] . To assess the presence of the cagA gene and distinguish between East Asian and Western alleles, we performed our cagA detection and cagA EPIYA typing ddPCR assays [18] on the antrum and corpus samples. Of the 46 subjects with detectable H. pylori 16S, all 46 were positive for the cagA gene by one or both assays. Of these 46 subjects, the cagA EPIYA typing ddPCR classified 37 (80%) as having either an East Asian or Western cagA allele. PCR amplification and sequencing of a portion of the cagA gene was performed for seven antrum samples that were negative by the cagA EPIYA typing assay. Of these seven samples, five were determined by sequencing to have EPIYA-C (Western cagA allele) and two had neither EPIYA-D nor EPIYA-C Fig 3. The five that were negative for the cagA EPIYA typing ddPCR assay but were determined to have EPIYA-C by sequencing all had the same three nucleotide differences in the forward primer region that could explain failure of the assay for these samples. One subject was determined to have an East Asian allele in the corpus sample by the cagA EPIYA typing ddPCR assay and an allele having neither an EPIYA-D nor an EPIYA-C in the antrum sample by sequencing.
Combining the results of the cagA EPIYA typing ddPCR assay and sequencing for the 46 subjects, 32 (70%) had the East Asian allele, 10 (22%) had a Western allele, one had only a non-East Asian, non-Western allele, and three were not determined. Being infected with an H. pylori strain with the East Asian cagA allele was significantly associated with gastric cancer (Fisher's Exact Test, p = 0.03) ( Table 2 ). Since we observed higher H. pylori loads in the stool among gastric cancer cases, we examined the relationship between H. pylori load in the stool and cagA allele. The median H. pylori stool load for subjects with an East Asian cagA allele was 33.5 H. pylori 16S copies per μg stool DNA (range 0-560) and for subjects with a Western cagA allele was 15.5 H. pylori 16S copies per μg stool DNA (range 0-1080) (Wilcoxon Exact Test p = 0.26). subjects grey, n = 23. Spearman Correlation Estimate = 0.7 (95% CI: 0.5-0.8). C. Gastric load (average of corpus and antrum) in subjects with (IM+, n = 18) or without (IM-, n = 24) histologic evidence of intestinal metaplasia (IM). Biopsy samples for histology were not available for 7 non-cancer cases. Points plotted on the X-axis represent subjects for which no H. pylori 16S rRNA gene was detected.
https://doi.org/10.1371/journal.pone.0202925.g001 ddPCR-based cagA-detection in stool samples shows high concordance with stomach samples
We extended our analysis of cagA genotypes by running the cagA EPIYA ddPCR typing assay on stool samples from 48 subjects. For one endoscopy case, there was insufficient stool DNA to run our cagA EPIYA ddPCR assay. We detected cagA in stool for 23/31 (73%) of subjects where we detected EPIYA-D type cagA in the stomach and 4/5 (80%) of subjects where we detected EPIYA-C type cagA in the stomach by the cagA EPIYA ddPCR assay. In all cases we detected the same EPIYA type in the stomach and stool samples by the cagA EPIYA ddPCR assay. 
Discussion
In this study, we leveraged recently developed ddPCR-based quantitative assays to explore differences in H. pylori load present in the stomach and shed into stool among cancer and noncancer cases undergoing surgery or upper GI endoscopy respectively at a hospital in China's Henan province, a region with high incidence of stomach cancer (38.13 per 100,000). At present, all methods for detecting active H. pylori infection (UBT, histology, PCR, culture) have limitations in specificity and sensitivity such that many studies require concordance between two or more methods. We used the clinically accepted UBT to screen for cases with H. pylori infection that were then analyzed by histology and ddPCR. Using UBT, our observations of 43% and 23% prevalence of H. pylori infection in cancer and non-cancer cases falls at the low end of that observed among symptomatic individuals in similar regions of China (30-80%) [23] [24] [25] . Of the UBT-positive cases enrolled in our study, 89% were positive by all three assays. In a separate study [26] , we showed that we could culture H. pylori from 88% of the UBT-positive cases. While ddPCR-based detection was slightly higher than culture-based detection from both stomach (94%) and stool (92%) samples our study did not include UBT-negative subjects [26] . New studies that include larger sample sizes, a mix of UBT-positive and UBTnegative cases and population-based sampling will thus be needed to assess the sensitivity and specificity of ddPCR-based assays for detecting H. pylori infection. While tissue alterations associated with cancer progression have been suggested to disfavor H. pylori colonization, we found similar loads in the stomach among cancer cases and noncancer cases. Additionally, histologic scores were not significantly different among cancer cases and non-cancer cases. The high correlation between loads measured from different biopsy samples and regions of the stomach within individuals suggests that patchy colonization within the stomach may be the exception rather than the rule in this population. Furthermore, the continued presence of H. pylori at high levels in the stomach may influence the rate or molecular phenotype of gastric cancer in the subset of individuals that remain colonized.
In contrast to the similar loads observed in the stomach, gastric cancer cases showed higher H. pylori loads in stool. Our previous population-based study in Costa Rica measured higher H. pylori loads in stool among subjects positive for CagA by serology [18] , prompting us to assay cagA status. However, all 46 subjects that had H. pylori 16S detected in the gastric samples also had cagA detected, so it was not possible to analyze the correlation between presence of cagA and H. pylori load in the stool in this population. While the East Asian cagA allele was significantly associated with gastric cancer, the allele was not associated with a higher H. pylori load in the stool. This suggests that the higher H. pylori load in subjects with gastric cancer is not dependent on presence of the cagA gene or East Asian cagA allele. Further studies will be necessary to determine at what point during progression to gastric cancer infected individuals have a higher H. pylori load in the stool and whether this could be used as a marker either for presence of gastric cancer or risk for eventual gastric cancer development.
In this study in Henan, China, we found the cagA gene to be uniformly present among study subjects but only 70% had the East Asian cagA allele, which was significantly associated with gastric cancer. Previous studies examining the cagA gene and East Asian allele in Chinese populations have found the prevalence of the cagA gene to be very high (75-90%) with the East Asian allele being predominant [27, 28] . While the cagA gene has been a good marker in Western populations for cancer risk, its utility in East Asian populations has been less clear since most strains have the cagA gene. In this population with a high prevalence of the cagA virulence gene, the East Asian allele could still provide a marker for gastric cancer risk.
The limited correlation between H. pylori loads measured in the stomach compared to the stool suggests shedding from the stomach depends on more than absolute abundance in the stomach. Possible mechanisms include altered growth rate, induction of epithelial turnover, and survival during transit through the lower GI tract. Further studies will need to be done to investigate the factors that contribute to the observed higher H. pylori load in the stool among gastric cancer subjects compared to non-cancer subjects despite a similar H. pylori load in the stomach. This will further our understanding of how pathological changes associated with gastric cancer development affect H. pylori colonization as well as what continued contribution H. pylori has to gastric cancer beyond initiation. 
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